Treatment as Prevention for the Uninfected
Sorry, this learning module is not available for mobile devices.
"HIV Treatment as Prevention: Ethics, Policy, and Implementation in the New York Region"
Resource ID: CM240
Roy Gulick, MD, MPH
Professor of Medicine and Chief of the Division of Infectious Diseases
Weill Medical College of Cornell University in New York City
Crystal Fuller, PhD, MPH
Associate Professor of Epidemiology
Mailman School of Public Health Columbia University
Bruce Schackman, PhD
Associate Professor of Public Health
Weill Cornell Medical College
Original Presentation: 10/12/2012
Web Posting: 3/12/2013
Dr. Gulick is Professor of Medicine and Chief of the Division of Infectious Diseases at Weill Medical College of Cornell University in New York City. He currently serves as Principal Investigator of the Cornell HIV Clinical Trials Unit of the AIDS Clinical Trials Group (ACTG), sponsored by the National Institutes of Health. He also serves as a Board Member of the International AIDS Society-USA, and as a member of the Panel on Clinical Practices for Treatment of HIV Infection of the U.S. Department of Health and Human Services.
Crystal Fuller, PhD, MPH is Associate Professor of Epidemiology at the Mailman School of Public Health Columbia University. Dr. Fuller received her PhD in Infectious Disease Epidemiology from Johns Hopkins University School of Public Health and her MPH from Tulane University School of Public Health. Dr. Fuller has conducted several HIV prevention and structural intervention research in the low-income marginalized populations in urban communities and is the author of numerous articles published in peer-reviewed journals.
Bruce Schackman is Associate Professor of Public Health and Chief of the Division of Health Policy in the Department of Public Health at Weill Cornell Medical College. He earned his Ph.D. in health policy with a concentration in decision sciences, his M.B.A and B.A. from Harvard University. Dr. Schackman's expertise is in economic evaluation of health interventions, cost-effectiveness and implementation research related to treatment of infectious diseases and substance abuse. Currently his research include economic evaluations of the management of HIV and hepatitis C, and opioid dependence treatment in the United States and the screening and treatment for HIV and syphilis in Haiti. Dr. Schackman's work was acknowledged with the Research in Action Award in 2005 by the Treatment Action Group.